Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997

Larry Cripe, Kevin Rader, Martin S. Tallman, Michael S. Gordon, Elisabeth Paietta, John Bennett, Donna Neuberg, Mark R. Litzow, Timothy E. O'Brien, Jacob M. Rowe

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Randomized trials of substituting high-dose cytarabine (HiDAC) for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. The hematological complications of intensification are considerable. GM-CSF after chemotherapy improved the survival of older patients in a randomized trial. Recombinant human interleukin 11, a thrombopoietic cytokine, reduced the incidence of chemotherapy-induced thrombocytopenia in patients with solid tumors. Therefore, 34 patients were treated, with newly diagnosed AML less than 56 years of age, with daunorubicin 45 mg/m2 on days 1-3, cytarabine 100 mg/m2 days 1-7 and cytarabine 2 g/m2 for 12 h on days 8-10 (7 + 3 + 3). rhIL-11 (50 μg/kg/day,) and GM-CSF (250 μg/kg/day) were administered subcutaneously from day 11 until recovery. The complete remission rate was 59% (90% C.I. 43-73%). The median time to recovery of neutrophils to >500 and platelets to ≥20,000 μl-1 was 27 days (95% C.I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care.

Original languageEnglish
Pages (from-to)823-827
Number of pages5
JournalLeukemia Research
Volume30
Issue number7
DOIs
StatePublished - Jul 2006

Fingerprint

Interleukin-11
Cytarabine
Granulocyte-Macrophage Colony-Stimulating Factor
Acute Myeloid Leukemia
oprelvekin
Drug Therapy
Daunorubicin
Thrombocytopenia
Neutrophils
Blood Platelets
Cytokines
Survival
Incidence
Neoplasms

Keywords

  • Acute myeloid leukemia
  • High-dose cytarabine
  • Induction chemotherapy
  • Recombinant interleukin 11
  • Thrombocytopenia

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction : ECOG 3997. / Cripe, Larry; Rader, Kevin; Tallman, Martin S.; Gordon, Michael S.; Paietta, Elisabeth; Bennett, John; Neuberg, Donna; Litzow, Mark R.; O'Brien, Timothy E.; Rowe, Jacob M.

In: Leukemia Research, Vol. 30, No. 7, 07.2006, p. 823-827.

Research output: Contribution to journalArticle

Cripe, Larry ; Rader, Kevin ; Tallman, Martin S. ; Gordon, Michael S. ; Paietta, Elisabeth ; Bennett, John ; Neuberg, Donna ; Litzow, Mark R. ; O'Brien, Timothy E. ; Rowe, Jacob M. / Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction : ECOG 3997. In: Leukemia Research. 2006 ; Vol. 30, No. 7. pp. 823-827.
@article{588be93a29894fb5bf2d867aea76ccd6,
title = "Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997",
abstract = "Randomized trials of substituting high-dose cytarabine (HiDAC) for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. The hematological complications of intensification are considerable. GM-CSF after chemotherapy improved the survival of older patients in a randomized trial. Recombinant human interleukin 11, a thrombopoietic cytokine, reduced the incidence of chemotherapy-induced thrombocytopenia in patients with solid tumors. Therefore, 34 patients were treated, with newly diagnosed AML less than 56 years of age, with daunorubicin 45 mg/m2 on days 1-3, cytarabine 100 mg/m2 days 1-7 and cytarabine 2 g/m2 for 12 h on days 8-10 (7 + 3 + 3). rhIL-11 (50 μg/kg/day,) and GM-CSF (250 μg/kg/day) were administered subcutaneously from day 11 until recovery. The complete remission rate was 59{\%} (90{\%} C.I. 43-73{\%}). The median time to recovery of neutrophils to >500 and platelets to ≥20,000 μl-1 was 27 days (95{\%} C.I. 27-30 days) and 25 days (95{\%} C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care.",
keywords = "Acute myeloid leukemia, High-dose cytarabine, Induction chemotherapy, Recombinant interleukin 11, Thrombocytopenia",
author = "Larry Cripe and Kevin Rader and Tallman, {Martin S.} and Gordon, {Michael S.} and Elisabeth Paietta and John Bennett and Donna Neuberg and Litzow, {Mark R.} and O'Brien, {Timothy E.} and Rowe, {Jacob M.}",
year = "2006",
month = "7",
doi = "10.1016/j.leukres.2005.11.006",
language = "English",
volume = "30",
pages = "823--827",
journal = "Leukemia Research",
issn = "0145-2126",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction

T2 - ECOG 3997

AU - Cripe, Larry

AU - Rader, Kevin

AU - Tallman, Martin S.

AU - Gordon, Michael S.

AU - Paietta, Elisabeth

AU - Bennett, John

AU - Neuberg, Donna

AU - Litzow, Mark R.

AU - O'Brien, Timothy E.

AU - Rowe, Jacob M.

PY - 2006/7

Y1 - 2006/7

N2 - Randomized trials of substituting high-dose cytarabine (HiDAC) for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. The hematological complications of intensification are considerable. GM-CSF after chemotherapy improved the survival of older patients in a randomized trial. Recombinant human interleukin 11, a thrombopoietic cytokine, reduced the incidence of chemotherapy-induced thrombocytopenia in patients with solid tumors. Therefore, 34 patients were treated, with newly diagnosed AML less than 56 years of age, with daunorubicin 45 mg/m2 on days 1-3, cytarabine 100 mg/m2 days 1-7 and cytarabine 2 g/m2 for 12 h on days 8-10 (7 + 3 + 3). rhIL-11 (50 μg/kg/day,) and GM-CSF (250 μg/kg/day) were administered subcutaneously from day 11 until recovery. The complete remission rate was 59% (90% C.I. 43-73%). The median time to recovery of neutrophils to >500 and platelets to ≥20,000 μl-1 was 27 days (95% C.I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care.

AB - Randomized trials of substituting high-dose cytarabine (HiDAC) for standard dose cytarabine (SDAC) during induction therapy for newly diagnosed AML have not demonstrated an improvement in the complete remission (CR) rate. Phase II trials of the scheduled administration of HiDAC after SDAC suggest an improved outcome. The hematological complications of intensification are considerable. GM-CSF after chemotherapy improved the survival of older patients in a randomized trial. Recombinant human interleukin 11, a thrombopoietic cytokine, reduced the incidence of chemotherapy-induced thrombocytopenia in patients with solid tumors. Therefore, 34 patients were treated, with newly diagnosed AML less than 56 years of age, with daunorubicin 45 mg/m2 on days 1-3, cytarabine 100 mg/m2 days 1-7 and cytarabine 2 g/m2 for 12 h on days 8-10 (7 + 3 + 3). rhIL-11 (50 μg/kg/day,) and GM-CSF (250 μg/kg/day) were administered subcutaneously from day 11 until recovery. The complete remission rate was 59% (90% C.I. 43-73%). The median time to recovery of neutrophils to >500 and platelets to ≥20,000 μl-1 was 27 days (95% C.I. 27-30 days) and 25 days (95% C.I. 24-29 days), respectively. The trial does not confirm the high CR rate observed in phase II trials, despite optimal supportive care.

KW - Acute myeloid leukemia

KW - High-dose cytarabine

KW - Induction chemotherapy

KW - Recombinant interleukin 11

KW - Thrombocytopenia

UR - http://www.scopus.com/inward/record.url?scp=33745437391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745437391&partnerID=8YFLogxK

U2 - 10.1016/j.leukres.2005.11.006

DO - 10.1016/j.leukres.2005.11.006

M3 - Article

C2 - 16413056

AN - SCOPUS:33745437391

VL - 30

SP - 823

EP - 827

JO - Leukemia Research

JF - Leukemia Research

SN - 0145-2126

IS - 7

ER -